<DOC>
	<DOCNO>NCT01346267</DOCNO>
	<brief_summary>RATIONALE : Acupressure wristbands may prevent reduce nausea cause chemotherapy . It yet know whether standard care effective without acupressure wristbands control acute delay nausea . PURPOSE : This randomized phase III trial study well acupressure wristband work without standard care control nausea young patient receive highly emetogenic chemotherapy .</brief_summary>
	<brief_title>Acupressure Controlling Nausea Young Patients Receiving Highly Emetogenic Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare control chemotherapy-induced nausea ( CIN ) acute phase provide 5-HT3 antagonist combine acupressure versus placebo acupressure child 4 18 year age treat chemotherapy include cisplatin ≥ 50 mg/m2/dose , ifosfamide plus etoposide/doxorubicin , cyclophosphamide plus anthracycline . Secondary - To compare control CIN delay phase provide 5-HT3 antagonist combine acupressure versus placebo acupressure child 4 18 year age treat chemotherapy include cisplatin ≥ 50 mg/m2/dose , ifosfamide plus etoposide/doxorubicin , cyclophosphamide plus anthracycline . - To compare control chemotherapy-induced vomit retching ( CIV ) acute delayed phase provide 5-HT3 antagonist combine acupressure versus placebo acupressure child 4 18 year age treat chemotherapy include cisplatin ≥ 50 mg/m2/dose , ifosfamide plus etoposide/doxorubicin , cyclophosphamide plus anthracycline . OUTLINE : This multicenter study . Patients stratify accord chemotherapy regimen anti-emetic Regimen 5-HT3 agonist ( ondansetron granisetron . ) Patients randomize 1 2 treatment arm . - Arm I : Patients wear Sea-Band acupressure wristband wrist begin approximately 30 minute prior first cisplatin-containing chemotherapy course continually 24 hour last chemotherapy dose ( acute phase ) , maximum 7 day next chemotherapy course start ( delayed phase ) . Patients allow take band intermittently ( 4 time day , 15 minute time ) relieve pressure bathe . Patients also receive standard care anti-emetic prophylaxis comprise granisetron , ondansetron , dexamethasone chemotherapy accord institutional physician preference . - Arm II : Patients wear placebo wristband wrist receive standard care anti-emetic prophylaxis chemotherapy patient arm I . Patients , parent , guardian instruct complete impatient outpatient diary nausea severity time emetic episode . Patients , parent , guardian also complete questionnaire acupressure end study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>INCLUSION CRITERIA : 4 18 year age , inclusive . The patient 's cognitive ability must consider parent healthcare professional least 4 yearold level . Newly diagnose ( i.e. , relapse ) malignancy . Patients require registered COG therapeutic trial . The patient 's current chemotherapy treatment plan must include least 1 course cisplatin ≥ 50 mg/m2/dose ifosfamide plus etoposide doxorubicin cyclophosphamide plus anthracycline . Patients may previously receive chemotherapy . The patient 's current treatment plan must include antiemetic regimen either ondansetron granisetron schedule basis . Patients may also receive dexamethasone antiemetic prophylaxis acute phase discretion treat physician . Patients ≥ 12 year old may also receive aprepitant conjunction dexamethasone antiemetic prophylaxis discretion treat physician . Patients need antiemetic treatment breakthrough nausea/vomiting may also receive antiemetic agent need ( PRN ) basis . The patient ( parent/guardian ) must Englishspeaking ( i.e. , able read speak English ) since PeNAT validate English . All patient and/or parent legal guardian must sign write informed consent ( patient assent also recommend applicable accord institution 's policy ) . EXCLUSION CRITERIA : Prior history acupressure use . Scheduled use antiemetic agent ondansetron , granisetron , dexamethasone aprepitant . Patients may receive antiemetic agent PRN breakthrough nausea/vomiting schedule basis</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>nausea vomit</keyword>
	<keyword>unspecified childhood solid tumor</keyword>
	<keyword>childhood central nervous system embryonal tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood central nervous system germinoma</keyword>
	<keyword>childhood central nervous system mixed germ cell tumor</keyword>
	<keyword>childhood central nervous system teratoma</keyword>
	<keyword>childhood central nervous system yolk sac tumor</keyword>
	<keyword>childhood mixed glioma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
	<keyword>untreated childhood visual pathway glioma</keyword>
	<keyword>childhood high-grade cerebellar astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebellar astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>untreated childhood cerebral astrocytoma</keyword>
	<keyword>untreated childhood subependymal giant cell astrocytoma</keyword>
	<keyword>childhood ependymoblastoma</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>untreated childhood pineoblastoma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>childhood medulloepithelioma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>childhood meningioma</keyword>
</DOC>